Interventional Pulmonology: A Brave New World.
Abstract Interventional pulmonology is a dynamic and evolving field in respiratory medicine. Advances have improved the ability to diagnose and manage diseases of the airways. A shift toward early detection of malignant disease has generated a focus on innovative diagnostic techniques. With patient populations living longer with malignant and benign diseases, the role for interventional bronchoscopy has grown. In cancer groups, novel immunotherapies have improved the prospects of clinical outcomes and reignited a focus on optimizing patient performance status to enable access to anticancer therapy. This review dis...
Source: Clinical Lung Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Kalsi HS, Thakrar R, Gosling AF, Shaefi S, Navani N Tags: Thorac Surg Clin Source Type: research

Bevacizumab-Induced Pneumonitis in a Patient With Metastatic Colon Cancer: A Case Report.
We report a case of a 79-year-old woman with metastatic colon cancer who presented with cough and dyspnea on exertion the day after initiation of bevacizumab. She was found to have bilateral airspace opacities on imaging. Infectious and cardiogenic etiologies of dyspnea were ruled out. Due to the temporal relationship with the initiation of chemotherapy, she was suspected to have developed bevacizumab-induced interstitial pneumonitis. She improved rapidly with high-dose steroids. Follow-up imaging showed resolution of infiltrates. This is the first reported case in the literature that directly links bevacizumab to intersti...
Source: Clinical Lung Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Pervaiz S, Homsy S, Narula N, Ngu S, Elsayegh D Tags: Clin Med Insights Circ Respir Pulm Med Source Type: research

A review of the role of MRI in diagnosis and treatment of early stage lung cancer.
Abstract Despite magnetic resonance imaging (MRI) being a mainstay in the oncologic care for many disease sites, it has not routinely been used in early lung cancer diagnosis, staging, and treatment. While MRI provides improved soft tissue contrast compared to computed tomography (CT), an advantage in multiple organs, the physical properties of the lungs and mediastinum create unique challenges for lung MRI. Although multi-detector CT remains the gold standard for lung imaging, advances in MRI technology have led to its increased clinical relevance in evaluating early stage lung cancer. Even though positron emissi...
Source: Clinical Lung Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Sim AJ, Kaza E, Singer L, Rosenberg SA Tags: Clin Transl Radiat Oncol Source Type: research

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
Abstract PURPOSE: Approximately 30% of NSCLC patients cannot obtain tissue sample or sufficient tissue sample for molecular subtyping. Cell-free circulating tumor DNA (ctDNA) in plasma is a potential alternative specimen type to assess genomic variants in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to identify the genomic alteration profile of ctDNA in real-world Chinese NSCLC patients. METHODS: A total of 325 subjects with pathological diagnosis of NSCLC were enrolled. 10 ml Peripheral blood was collected in streck tube, and ctDNA NGS analysis was carried out using an...
Source: Clinical Lung Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Chen H, Wang A, Wang J, He Z, Mao Y, Liu L Tags: J Cancer Res Clin Oncol Source Type: research

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
CONCLUSION: Abnormal activation of EGFR may induce wtEGFR NSCLC cell resistance to cisplatin. The combined effects of cisplatin/gefitinib suggest that gefitinib, as a combination therapy for patients with cisplatin-resistant wtEGFR NSCLC should be considered. PMID: 32342201 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, Zhang R, Liu X, Zhou S, Wang R, Liu J, Tang X Tags: J Cancer Res Clin Oncol Source Type: research

Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.
CONCLUSION: The current study provided a better understanding of the ceRNA network in the progression of LUSC and laid a theoretical foundation for LUSC prognosis. PMID: 32356177 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Ju Q, Zhao YJ, Ma S, Li XM, Zhang H, Zhang SQ, Yang YM, Yan SX Tags: J Cancer Res Clin Oncol Source Type: research

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
CONCLUSIONS: Lung adenocarcinoma patients harboring EGFR and co-mutational tumor suppressor genes should be regarded as a unique subgroup. PMID: 32361787 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 17, 2020 Category: Cancer & Oncology Authors: Zhao Y, Pan Y, Cheng C, Zheng D, Zhang Y, Gao Z, Fu F, Li H, Zheng S, Zhuge L, Mao H, Kuang M, Tao X, Peng Y, Hu H, Xiang J, Li Y, Sun Y, Chen H Tags: J Cancer Res Clin Oncol Source Type: research

Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing.
Conclusion: This analysis uses TDABC to estimate the relative internal costs of various RT strategies associated with treating oligometastatic NSCLC. This methodology will become increasingly relevant to each organization in context of the anticipated mandate of alternative/bundled payment models for radiation oncology by the Centers for Medicare and Medicaid Services. PMID: 32529054 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 13, 2020 Category: Cancer & Oncology Authors: Pezzi TA, Ning MS, Thaker NG, Boyce-Fappiano D, Gjyshi O, Olivieri ND, Guzman AB, Incalcaterra JR, Mesko S, Gandhi S, Chun S, Tang C, Frank SJ, Gomez DR Tags: Clin Transl Radiat Oncol Source Type: research

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer.
Conclusion: Incidence of grade ≥2 RP was 36% after CCRT followed by durvalumab for LA-NSCLC, but did not significantly differ from those of patients treated with CCRT alone. Lung dose-volume parameters were significantly correlated with RP. PMID: 32529055 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 13, 2020 Category: Cancer & Oncology Authors: Saito S, Abe T, Kobayashi N, Aoshika T, Ryuno Y, Igari M, Hirai R, Kumazaki Y, Miura Y, Kaira K, Kagamu H, Noda SE, Kato S Tags: Clin Transl Radiat Oncol Source Type: research

Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report.
Abstract Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer, accounting for 3% of all lung cancers. The prognosis is poor and the standard therapy has not been well established. Herein, we report a case of advanced LCNEC of the lung that responded to nivolumab. The patient was a 62-year old man with stage IVB LCNEC of the lung. The disease progressed following the administration of second-line chemotherapy, and he was treated with nivolumab 3 mg/kg as the third-line treatment. Although treatment was ceased after two cycles due to interstitial pneumonia, the disease remained stable ...
Source: Clinical Lung Cancer - June 7, 2020 Category: Cancer & Oncology Authors: Takimoto Sato M, Ikezawa Y, Sato M, Suzuki A, Kawai Y Tags: Mol Clin Oncol Source Type: research

Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.
Abstract The COVID-19 pandemia is affecting people worldwide. Most of the patients suffered of a respiratory disease that will progress to an acute respiratory distress syndrome (ARDS). SARS-CoV-2 pneumonia severely ill patients, develop a systemic inflammatory response with a Cytokine Release Syndrome (CRS), that is characterized by a sudden increase in several pro-inflammatory cytokines, mainly IL-1, IL-6 and TNF-alfa by activated macrophages (M1 phenotype). Blocking IL-6 with tocilizumab and using respirator equipment seems to be a very important issue in this (SARS-CoV-2) pneumonia, but not all patients are re...
Source: Clinical Lung Cancer - May 8, 2020 Category: Cancer & Oncology Authors: Lara PC, Burgos J, Macias D Tags: Clin Transl Radiat Oncol Source Type: research

Association between rs1229984 in ADH1B and cancer prevalence in a Japanese population.
In conclusion, there was no significant association between rs1229984 and odds of overall or specific cancers except in lung cancer where His/His genotype decreased odds. To the best of our knowledge, the association between His/His and decreased odds of lung cancer is a novel finding. These findings require further validation in larger studies. PMID: 32337031 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 28, 2020 Category: Cancer & Oncology Authors: Govind P, Pavethynath S, Sawabe M, Arai T, Muramatsu M Tags: Mol Clin Oncol Source Type: research

Infiltration of the thyroid gland by non-thyroid malignancy: A literature review reveals this to be an unusual cause of hyperthyroidism.
Conclusion: Malignancy-associated hyperthyroidism has a similar underlying mechanism to subacute thyroiditis, in so much as there is damage or destruction of thyroid tissue. In cases of subacute thyroiditis this damage is self-limited, and there is recovery of thyroid function. In some cases of thyroiditis associated with malignancy there may be thyroid gland recovery as the underlying malignancy is treated and controlled. However, if the malignancy progresses, eventual hypothyroidism is likely to ensue. PMID: 32154117 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 12, 2020 Category: Cancer & Oncology Authors: Jonklaas J Tags: J Clin Transl Endocrinol Source Type: research

Correlation of normal lung density changes with dose after stereotactic body radiotherapy (SBRT) for early stage lung cancer.
Abstract Background and Purpose: To investigate the correlation between normal lung CT density changes with dose accuracy and outcome after stereotactic body radiation therapy (SBRT) for patients with early stage non-small-cell lung cancer (NSCLC). Materials and Methods: Thirty-one patients (with a total of 33 lesions) with non-small cell lung cancer were selected out of 270 patients treated with SBRT at a single institution between 2003 and 2009. Out of these 31 patients, 10 patients had developed radiation pneumonitis (RP). Dose distributions originally planned using a 1-D pencil beam-based dose algorithm w...
Source: Clinical Lung Cancer - March 8, 2020 Category: Cancer & Oncology Authors: Al Feghali KA, Wu QC, Devpura S, Liu C, Ghanem AI, Wen NW, Ajlouni M, Simoff MJ, Movsas B, Chetty IJ Tags: Clin Transl Radiat Oncol Source Type: research

Hemoptysis with no malignancy suspected on computed tomography rarely requires bronchoscopy.
Conclusions: The vast majority of hemoptysis cases with no malignancy suspected on computed tomography were cryptogenic and all were benign. Bronchoscopy may be reserved for patients with specific conditions suspected and those with persistent symptomatology. PMID: 32128078 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Petersen CL, Weinreich UM Tags: Eur Clin Respir J Source Type: research

Fluoroscopy guided percutaneous biopsy in combination with bronchoscopy and endobronchial ultrasound in the diagnosis of suspicious lung lesions - the triple approach.
ger U Abstract Flexible bronchoscopy and endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) are the pulmonologists´ basic procedures for the biopsy of suspicious lung lesions. If inconclusive, other guiding-modalities for tissue sampling are needed, computed tomography performed by a radiologist, or - if available - radial EBUS or electromagnetic navigation biopsy. We wanted to investigate if same-day X-ray fluoroscopy-guided transthoracic fine-needle aspiration biopsy (F-TTNAB) performed by the pulmonologist immediately after bronchoscopy and EBUS is a feasible alternative. We retr...
Source: Clinical Lung Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Sidhu JS, Salte G, Christiansen IS, Naur TMH, Høegholm A, Clementsen PF, Bodtger U Tags: Eur Clin Respir J Source Type: research

Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review.
Abstract Approximately one-third of all non-small-cell lung cancer (NSCLC) are locally-advanced at diagnosis, and 15-17% of these tumors are unresectable at presentation. Definitive chemo-radiotherapy (CRT) represents the standard therapeutic approach. However, the literature has shown that only 15% of patients are alive at 5 years and this percentage has remained unchanged despite various attempts of improvement. The recent introduction of immunotherapy has not only strongly changed the clinical scenario but has also drawn attention to a stage of disease apparently forgotten for decades. Stage III NSCLC can ...
Source: Clinical Lung Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Baldini E, Tibaldi C, Delli Paoli C Tags: Clin Transl Oncol Source Type: research

The rationale and toxicity of combined cranial radiotherapy and immune checkpoint inhibitors in non-small cell lung cancer.
Abstract Cranial radiation therapy (CRT) remains to be the foundation stone of the management of brain metastases in non-small cell lung cancer (NSCLC). Nevertheless, the care of NSCLC, recently, has been remarkably reshaped by the immune checkpoint inhibitors (ICIs), such as programmed death protein-1 and programmed death ligand-1 inhibitors, which even showed some efficacy in brain metastases. Furthermore, radiotherapy, traditionally regarded as a therapy via localized cytotoxicity, recently was reported to trigger a systemic immune response, thus probably enhancing the antitumor effect of ICIs. Preliminary data...
Source: Clinical Lung Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Chen Y, Zhuang H, Wang J Tags: Asia Pac J Clin Oncol Source Type: research

Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma.
This study aimed to identify the prognostic factors for pStage I lung adenocarcinoma. METHODS: We retrospectively reviewed 208 patients with pStage I adenocarcinomas who underwent curative resection in our institute between 2006 and 2013. The maximum standardized uptake value (SUVmax) on [F18]-fluoro-deoxy-D-glucose positron emission tomography-computed tomography (PET/CT) was evaluated. Adenocarcinomas were categorized into the following histologic groups: group 0 (minimally invasive adenocarcinoma and lepidic predominant adenocarcinoma), group 1 (papillary predominant adenocarcinoma), and group 2 (acinar predominant...
Source: Clinical Lung Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Kawakita N, Toba H, Kawakami Y, Takizawa H, Bando Y, Otuska H, Matsumoto D, Takashima M, Tsuboi M, Yoshida M, Kondo K, Tangoku A Tags: Int J Clin Oncol Source Type: research

IRF4 instructs effector Treg differentiation and immune suppression in human cancer.
Abstract The molecular mechanisms responsible for the high immunosuppressive capacity of CD4+ regulatory T cells (Tregs) in tumors are poorly known. High-dimensional single cell profiling of T cells from chemotherapy-naïve individuals with non-small cell lung cancer identified the transcription factor IRF4 as specifically expressed by a subset of intratumoral CD4+ effector Tregs with superior suppressive activity. In contrast to the IRF4- counterparts, IRF4+ Tregs expressed a vast array of suppressive molecules, and their presence correlated with multiple exhausted subpopulations of T cells. Integration of tr...
Source: Clinical Lung Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Alvisi G, Brummelman J, Puccio S, Mazza EMC, Paoluzzi Tomada E, Losurdo A, Zanon V, Peano C, Colombo FS, Scarpa A, Alloisio M, Vasanthakumar A, Roychoudhuri R, Kallikourdis M, Pagani M, Lopci E, Novellis P, Blume J, Kallies A, Veronesi G, Lugli E Tags: J Clin Invest Source Type: research

ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.
CONCLUSION: False negative of ALK IHC, FISH and NGS results were found in our cohort, but none was false ALK positive. False ALK negatives should be more concerned than false positives. ALK rearrangements with cryptic ALK fusion patterns could be identified using our algorithm. Non-squamous non-small cell lung cancer was recommended for priority detection. PMID: 32128622 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Liu Y, Wu S, Shi X, Liang Z, Zeng X Tags: J Cancer Res Clin Oncol Source Type: research

Candidate lncRNA-microRNA-mRNA networks in predicting non-small cell lung cancer and related prognosis analysis.
CONCLUSION: Based on this, the prognosis in both lung squamous cell carcinoma and lung adenocarcinoma was analyzed. We have also constructed a ceRNA network to provide a basis for the study of ceRNA in lung adenocarcinoma and lung squamous cell carcinoma. PMID: 32124023 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Li S, Cui Z, Zhao Y, Ma S, Sun Y, Li H, Gao M, Li N, Wang Y, Tong L, Song M, Yin Z Tags: J Cancer Res Clin Oncol Source Type: research

Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival.
This study retrospectively reviewed 200 patients with 324 BM treated with one fraction (15-21 Gy) or 5-10 fractions (25-40 Gy) between January 2010 and August 2016. 26.5% of patients received whole brain radiotherapy (WBRT) and 25% initial surgery. Demographics, prognostic scales, systemic and local controls, patterns of relapse and rescue, toxicity, and cause of death were analyzed. A stratified analysis by primary tumor was done. RESULTS: Median overall survival (OS) was 8 months from SRS/HFSRT. Breast cancer patients had a median OS of 17 months, followed by renal (11 months), lung (8 ...
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Sallabanda M, García-Berrocal MI, Romero J, García-Jarabo V, Expósito MJ, Rincón DF, Zapata I, Magallón MR Tags: Clin Transl Oncol Source Type: research

Puerarin 6 ″-O-xyloside suppresses growth, self-renewal and invasion of lung cancer stem-like cells derived from A549 cells via regulating Akt/c-Myc signalling.
In conclusion, PXY can block the traits of LCSLCs, indicating that PXY may be a candidate compound for lung adenocarcinoma therapy via eliminating LCSLCs. PMID: 32124474 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Tao X, Yin Y, Lian D, Gu H, Chen W, Yang L, Yin G, Liu P, Li L, Wei Y, Xie Z, Liu F, Sui H, Yan D, Tao W Tags: Clin Exp Pharmacol Physiol Source Type: research

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group.
Abstract The Japan Clinical Oncology Group Lung Cancer Study Group has been carrying out clinical studies, exploring new strategies of treatment, supportive therapies (antiemetics, etc.), etc., for a variety of cancers, including not only small cell lung cancer and non-small cell lung cancer but also rare chest tumours (represented by thymoma) and cancer-associated conditions (cancerous pericarditis, cancerous pleuritis, etc.). In this review, an overview of all studies conducted from 1985 to 2019 is provided. PMID: 32115625 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Horinouchi H, Ohe Y Tags: Jpn J Clin Oncol Source Type: research

The Prevalence and Burden of Non-AIDS Comorbidities among Women living with or at-risk for HIV Infection in the United States.
Abstract INTRODUCTION: The prevalence and burden of age-related non-AIDS comorbidities (NACM) is poorly characterized among women living with HIV (WLWH). METHODS: Virologically-suppressed WLWH and HIV-seronegative participants followed in the Women's Interagency HIV Study (WIHS) through ≥2009 (when>80% WLWH used antiretroviral therapy) were included, with outcomes measured through 3/31/2018. Covariates, NACM number and prevalence were summarized at most recent WIHS visit. We used linear regression models to determine NACM burden by HIV serostatus and age. RESULTS: Among 3232 women (2309 WLWH, 923 H...
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Collins LF, Sheth AN, Mehta CC, Naggie S, Golub ET, Anastos K, French AL, Kassaye S, Taylor T, Fischl MA, Adimora AA, Kempf MC, Palella FJ, Tien PC, Ofotokun I Tags: Clin Infect Dis Source Type: research

Initial experience of robotic anatomical segmentectomy for non-small cell lung cancer.
CONCLUSION: In our initial experience of robotic anatomical segmentectomy for early stage non-small cell lung cancer, the procedure seems to be safe and feasible. PMID: 32115630 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Kagimoto A, Tsutani Y, Izaki Y, Handa Y, Mimae T, Miyata Y, Okada M Tags: Jpn J Clin Oncol Source Type: research

CircRNA_103762 promotes multidrug resistance in NSCLC by targeting DNA damage inducible transcript 3 (CHOP).
CONCLUSION: Together, we demonstrated that circRNA_103762 is upregulated in NSCLC and functions as an oncogene in NSCLC, and circRNA_103762 enhanced MDR by inhibited CHOP expression in NSCLC cells. These results will help us understand the MDR of NSCLC, providing better effective therapy strategies for patients. PMID: 32118311 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Xiao G, Huang W, Zhan Y, Li J, Tong W Tags: J Clin Lab Anal Source Type: research

A high serum-free fatty acid level is associated with cancer.
CONCLUSION: Our study provides clinical evidence to support that fatty acid metabolism is associated with cancers and demonstrates that a high FFA level in the serum may be an indicator of cancer. PMID: 31773260 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Zhang L, Han L, He J, Lv J, Pan R, Lv T Tags: J Cancer Res Clin Oncol Source Type: research

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
CONCLUSION: The potential therapeutic value of fluzoparib for increasing the radiation sensitivity of NSCLC is well confirmed. Moreover, our findings of high mutation frequencies among HR genes suggest that PARP1 inhibition may be an effective treatment strategy for advanced non-small cell lung cancer patients. PMID: 31786739 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P Tags: J Cancer Res Clin Oncol Source Type: research

Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information.
Abstract PURPOSE: Epidermal growth factor receptor (EGFR) mutation testing has several limitations. Therefore, we built predictive models to determine the EGFR mutation status of patients and guide therapeutic decision-making. METHODS: We collected data from 320 patients with lung carcinoma, including sex, age, smoking history, serum tumour marker levels, maximum standardized uptake value, pathological results, computed tomography images, and EGFR mutation status. Artificial neural network (ANN) models based on multiple clinical characteristics were proposed to predict EGFR mutation status. RESULTS: A tr...
Source: Clinical Lung Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Qin X, Wang H, Hu X, Gu X, Zhou W Tags: J Cancer Res Clin Oncol Source Type: research

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
CONCLUSION: Despite the poor outcomes with ICI treatment in patients with advanced and recurrent NSCLC who had liver metastasis, some characteristics among patients with liver metastasis may be associated with prognosis. PMID: 31828427 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Kitadai R, Okuma Y, Hakozaki T, Hosomi Y Tags: J Cancer Res Clin Oncol Source Type: research

Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients.
Abstract PURPOSE: We combined conventional clinical and pathological characteristics and pathological architectural grading scores to develop a prognostic model to identify a specific group of patients with stage I lung adenocarcinomas with poor survival following surgery. METHODS: This retrospective study included 198 patients with stage I lung adenocarcinomas recruited from 2004 to 2013. Multivariate analyses were used to confirm independent risk factors, which were checked for internal validity using the bootstrapping method. The prognostic scores, derived from β-coefficients using the Cox regression ...
Source: Clinical Lung Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Liu DH, Ye ZH, Chen S, Sun XS, Hou JY, Zhao ZR, Long H Tags: J Cancer Res Clin Oncol Source Type: research

Statistical analysis plan for "A randomised, controlled study to evaluate the effects of switching from cigarette smoking to using a tobacco heating product on health effect indicators in healthy subjects".
Statistical analysis plan for "A randomised, controlled study to evaluate the effects of switching from cigarette smoking to using a tobacco heating product on health effect indicators in healthy subjects". Contemp Clin Trials Commun. 2020 Mar;17:100535 Authors: Camacho OM, Hedge A, Lowe F, Newland N, Gale N, McEwan M, Proctor C Abstract Tobacco harm reduction strategies aim to substitute smoking with potentially reduced risk products (PRRPs) such as e-cigarettes and tobacco-heating products (THPs). The health benefits of switching from smoking to PRRPs is unknown. A randomised controlled tr...
Source: Clinical Lung Cancer - February 21, 2020 Category: Cancer & Oncology Authors: Camacho OM, Hedge A, Lowe F, Newland N, Gale N, McEwan M, Proctor C Tags: Contemp Clin Trials Commun Source Type: research

Lack of association between Screencell-detected circulating tumour cells and long-term survival of patients undergoing surgery for non-small cell lung cancer: A pilot clinical study.
Abstract Circulating tumour cells (CTCs) are cancer cells of epithelial origin that are present in peripheral blood samples. ScreenCell detection of CTCs and the association with long term survival in non-small cell lung cancer (NSCLC) patients was evaluated in the present study. A total of 33 patients undergoing surgical resection for NSCLC were recruited. Patients were followed up for 5-years post-operatively. Pre-operative patient bloods samples were processed using ScreenCell. CTCs were detected in 26 (79%) patients. In patients who were positive for CTCs, a total of 9 (35%) patients succumbed to the disease, ...
Source: Clinical Lung Cancer - February 20, 2020 Category: Cancer & Oncology Authors: Barr J, Chudasama D, Rice A, Karteris E, Anikin V Tags: Mol Clin Oncol Source Type: research

Outcome of patients with lung cancer and severe psychiatric disorder admitted to a medical psychiatric unit.
Abstract The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, ...
Source: Clinical Lung Cancer - February 20, 2020 Category: Cancer & Oncology Authors: Takehara T, Tani T, Takiue H, Takeshita R, Iwamaru A, Yamamoto T, Koh H Tags: Mol Clin Oncol Source Type: research

Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: A pilot study.
Abstract We have developed a metallic micro-cavity array filter and an automated detection system for capturing circulating tumor cells (CTCs). In this single institutional pilot study, we assessed the ability of this device to detect CTCs in patients with lung cancer at each stage. Patients diagnosed with lung cancer, undergoing planned surgery for lung cancer, or suspected of having lung cancer were recruited (40 recruited and 2 excluded). Blood samples were obtained from the patients and 3 ml whole blood was applied to the device without any preparation. The captured cells were stained to differentiate the nucl...
Source: Clinical Lung Cancer - February 20, 2020 Category: Cancer & Oncology Authors: Ichimura H, Nawa T, Yamamoto Y, Shimizu K, Kobayashi K, Kitazawa S, Kanbara H, Odagiri T, Endo K, Matsunaga T, Nakamura S, Yagi S, Sato Y Tags: Mol Clin Oncol Source Type: research

Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial.
Conclusion: Nitroglycerin did not improve OS of NSCLC patients treated with (chemo-)radiotherapy. A general ability of nitroglycerin to reduce hypoxia was not shown. PMID: 32021913 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 7, 2020 Category: Cancer & Oncology Authors: Reymen BJT, van Gisbergen MW, Even AJG, Zegers CML, Das M, Vegt E, Wildberger JE, Mottaghy FM, Yaromina A, Dubois LJ, van Elmpt W, De Ruysscher D, Lambin P Tags: Clin Transl Radiat Oncol Source Type: research

Lung Cancer 2020: Epidemiology, Etiology, and Prevention.
Abstract Despite advances in our understanding of risk, development, immunologic control, and treatment options for lung cancer, it remains the leading cause of cancer death. Tobacco smoking remains the predominant risk factor for lung cancer development. Nontobacco risk factors include environmental and occupational exposures, chronic lung disease, lung infections, and lifestyle factors. Because tobacco remains the leading risk factor for lung cancer, disease prevention is focused on smoking avoidance and cessation. Other prevention measures include healthy diet choices and maintaining a physically active lifesty...
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Bade BC, Dela Cruz CS Tags: Clin Chest Med Source Type: research

Biomarkers in Lung Cancer.
This article provides an overview of lung cancer biomarker development, focusing on clinical utility and highlighting 2 unmet clinical needs: selection of high-risk patients for lung cancer screening and differentiation of early lung cancer from benign pulmonary nodules. The authors highlight biomarkers under development and those lung cancer screening and nodule management biomarkers post-clinical validation. Finally, trends in lung cancer biomarker development that may improve accuracy and accelerate implementation in practice are discussed. PMID: 32008624 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Sears CR, Mazzone PJ Tags: Clin Chest Med Source Type: research

Bronchoscopic Diagnostic Procedures Available to the Pulmonologist.
Abstract In the diagnosis of lung cancer, pulmonologists have several tools at their disposal. From the tried and true convex probe endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration to robotic bronchoscopy for peripheral lesions and new technology to unblind the biopsy tools, this article elucidates and expounds on the tools currently available and being developed for lung cancer diagnosis. PMID: 32008625 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Burks AC, Akulian J Tags: Clin Chest Med Source Type: research

Therapeutic Bronchoscopic Techniques Available to the Pulmonologist: Emerging Therapies in the Treatment of Peripheral Lung Lesions and Endobronchial Tumors.
Abstract Therapeutic bronchoscopy for both endobronchial tumors and peripheral lung cancer is rapidly evolving. The expected increase in early stage lung cancer detection and significant improvement in near real-time imaging for diagnostic bronchoscopy has led to the development of bronchoscopy-delivered ablative technologies. Therapies targeting obstructing central airway tumors for palliation and as a method of local disease control, patient selection and patient-centered outcomes have been areas of ongoing research. This review focuses on patient selection when considering therapeutic bronchoscopy and new and d...
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Aboudara M, Rickman O, Maldonado F Tags: Clin Chest Med Source Type: research

The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment.
Abstract Lung cancer is a heterogeneous disease with abundant genomic alterations. Chronic dysregulated airway inflammation facilitates lung tumorigenesis. In contrast, antitumor host immune responses apply continuous selective pressure on the tumor cells during the evolutionary course of the disease. Unprecedented advances in integrative genomic, epigenomic, and cellular profiling of lung cancer and the tumor microenvironment are enhancing the understanding of pulmonary tumorigenesis. This understanding in turn has led to advancements in lung cancer prevention and early detection strategies, and the development o...
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Salehi-Rad R, Li R, Paul MK, Dubinett SM, Liu B Tags: Clin Chest Med Source Type: research

Primary and Secondary Prevention of Lung Cancer: Tobacco Treatment.
Abstract Tobacco dependence is the most consequential target to reduce the burden of lung cancer worldwide. Quitting after a cancer diagnosis can improve cancer prognosis, overall health, and quality of life. Several oncology professional organizations have issued guidelines stressing the importance of tobacco treatment for patients with cancer. Providing tobacco treatment in the context of lung cancer screening is another opportunity to further reduce death from lung cancer. In this review, the authors describe the current state of tobacco dependence treatment focusing on new paradigms and approaches and their pa...
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Kathuria H, Neptune E Tags: Clin Chest Med Source Type: research

Lung Cancer in Women: A Modern Epidemic.
Abstract Lung cancer in women is a modern epidemic and a major health crisis. Cigarette smoking remains the most important risk factor for lung cancer, and unfortunately smoking rates are either stabilized or continue to increase among women. Women may not be more susceptible to the carcinogenic effects of tobacco, but the biology of lung cancer differs between the sexes. This paper summarizes the biological sex differences in lung cancer, including molecular abnormalities, growth factor receptors, hormonal influences, DNA repair capacity, as well as differences in the histology and treatment outcomes of lung canc...
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: MacRosty CR, Rivera MP Tags: Clin Chest Med Source Type: research

Lung Cancer Pathology: Current Concepts.
Abstract Lung cancer can be diagnosed based on histologic biopsy or cytologic specimens. The 2015 World Health Organization Classification of Lung Tumors addressed the diagnosis of lung cancer in resection specimens and in small biopsies and cytology specimens. For these small specimens, diagnostic terms and criteria are recommended. Targetable mutations such as EGFR and ALK rearrangements emphasize the importance of managing these small specimens for molecular testing. PMID: 32008630 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Travis WD Tags: Clin Chest Med Source Type: research

Lung Cancer Screening: Patient Selection and Implementation.
Abstract Robust evidence exists in support of lung cancer (LC) screening with low-dose computed tomography in patients at high risk of developing LC; however, judicious patient selection is necessary to obtain optimal benefit while minimizing harm. Several professional societies have published recommendations regarding patient selection criteria for screening. Multiple risk prediction models that include additional patient-specific risk factors have since been developed to more accurately predict risk of developing LC. Implementation of a new screening program requires thorough multidisciplinary planning and maint...
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Thomas NA, Tanner NT Tags: Clin Chest Med Source Type: research

Passion, Perseverance, and Quantum Leaps: Lung Cancer in the Twenty-First Century.
PMID: 32008633 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Rivera MP, Matthay RA Tags: Clin Chest Med Source Type: research

Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer.
This article discusses the molecular characteristics of the main lung cancer subtypes and discusses the current guidelines and novel targeted therapies, including checkpoint immunotherapy. PMID: 32005431 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 3, 2020 Category: Cancer & Oncology Authors: Ruiz-Cordero R, Devine WP Tags: Surg Pathol Clin Source Type: research

Lung Cancer Staging.
Abstract Lung cancer staging is a foundation of patient care, informing management decisions and prognosis. This comprehensive overview of the current 8th edition American Joint Committee on Cancer Cancer Staging Manual addresses common difficulties in staging, such as measuring the invasive component of adenocarcinomas and staging multiple lung nodules. PMID: 32005435 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 3, 2020 Category: Cancer & Oncology Authors: Kutob L, Schneider F Tags: Surg Pathol Clin Source Type: research